RecruitingNot ApplicableNCT05685108

Optimizing Ultrasound-induced Anti-inflammation in Human Subjects


Sponsor

University of Virginia

Enrollment

40 participants

Start Date

Sep 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a feasibility study to determine whether pulsed ultrasound stimulation targeting the splenic nerve or the cervical vagus nerve can elicit an anti-inflammatory immune response in healthy volunteers.


Eligibility

Min Age: 25 YearsMax Age: 50 Years

Inclusion Criteria7

  • Male or female, aged 25-50 years
  • Provision of signed and dated informed consent form
  • Able to comprehend the study goals and procedures, stated willingness to comply with all study procedures, and availability for the duration of the study
  • Considered English proficient so that the subject can follow verbal commands during the ultrasound procedure
  • In good general health, as evidenced by medical history
  • Laboratory results indicating normal blood count and adequate organ function
  • Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion Criteria21

  • Chronic medical conditions, including cancer (in remission or active cancer), cerebrovascular disease, chronic kidney disease, heart conditions (such as heart failure, coronary artery disease, cardiomyopathies), lung disease, liver disease, hypertension, diabetes mellitus type 1 and 2, human immunodeficiency virus infection, primary immunodeficiencies, solid organ or hematopoietic cell transplantation, tuberculosis, and cystic fibrosis, autoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel disease), sickle cell anemia or other anemia syndromes
  • Mean systolic and diastolic blood pressure values during screening of ≥160 and ≥100 mm Hg, respectively, hypertension on non-selective beta-blockers and/or alpha-methyl dopa, or hypertension requiring more than two anti-hypertension medications
  • Obesity (body mass index ≥30 kg/m2)
  • Use of anti-inflammatory or immunomodulatory medication, such as non- steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or other immunosuppressants, within one week of receiving ultrasound delivery
  • Use of anticoagulant drugs (e.g., coumadin, direct oral anticoagulants) or antiplatelet drugs (e.g., aspirin, clopidogrel) within one week of receiving ultrasound delivery
  • Pregnancy, breastfeeding, or planning to become pregnant during the study
  • Active bacterial or viral infection; febrile illness within 2 weeks of receiving ultrasound delivery
  • Known allergic reactions to ultrasound gel
  • Treatment with another investigational drug or other intervention within 1 month of receiving ultrasound delivery
  • Any vaccination received within 1 month of receiving ultrasound delivery
  • Current smoker or nicotine use within 2 weeks of receiving ultrasound delivery
  • Use of recreational drugs within 2 weeks of receiving ultrasound delivery
  • History of arrythmia (e.g., clinically significant bradycardia, atrial flutter, atrial fibrillation, ventricular arrythmias)
  • History of deep vein thrombosis or pulmonary embolism
  • History of bleeding disorder
  • History of seizure
  • History of unilateral or bilateral vagotomy
  • Participants with an implantable medical device, such as pacemaker, hearing aid implant, or any implanted electronic device
  • Surgery or traumatic injury (e.g., visceral injury, cerebral injury) in the past 3 months
  • Prior surgery on thyroid or parathyroid glands, esophagus, stomach, or spleen
  • Participant is considered by the Investigator, after reviewing medical and psychiatric history, physical examination, and laboratory evaluations, to be unsuitable for any other reason that may either place the patient at increased risk during participation or interfere with the interpretation of the study. outcomes.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEUltrasound stimulation intensity

A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.

DEVICEUltrasound stimulation site

A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.


Locations(1)

University of Virginia, Division of Nephrology; Center for Immunity, Inflammation & Regenerative Medicine

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05685108


Related Trials